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Background: Primary adrenal lymphoma (PAL) is an extremely rare subtype of extranodal non-Hodgkin’s
lymphoma. Some researchers have reported some of the characteristics of PAL and its association with poor
prognosis; however, the clinicopathological features of PAL remain to be elucidated.
Methods: From 2008 to 2011 we experienced seven cases of PAL in our institutions. We retrospectively analyzed
the clinical and pathological features of these patients.
Results: The patients ranged in age from 50 to 85 years, with a median of 71 years. The overall male:female ratio
was 6:1. All seven patients were diagnosed with diffuse large B-cell lymphoma (DLBCL) pathologically. Bilateral
adrenal involvement was confirmed in five patients. The median largest tumor diameter at diagnosis was 58 mm.
The Ki-67 index was generally high (>70%). All patients were treated with rituximab-containing chemotherapy, and
central nervous system (CNS) prophylaxis was conducted for three patients. One patient with CNS involvement at
the time of the diagnosis also received whole-brain radiation. The overall survival rate at two years was 57%
(median follow-up; 24.8 months). It is noteworthy that the three patients who received a full course of the
rituximab-containing regimen and CNS prophylaxis are currently alive without disease relapse, and that none of the
seven patients died due to progression of lymphoma.
Conclusions: Primary adrenal DLBCL can be a clinically aggressive disease entity. Rituximab-containing
chemotherapy combined with CNS prophylaxis could be a reasonable option for the treatment of PAL; however,
analyses of more PAL cases are needed for the establishment of this strategy.
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Malignant lymphoma primarily arising in the adrenal
gland, i.e., primary adrenal lymphoma (PAL), is an ex-
tremely rare disease and accounts for less than 1% of all
non-Hodgkin’s lymphoma. Around 100 cases of PAL have
been reported in the English literature to date; with the
exception of a few investigational reports based on several
cases, most have been single case reports and literature re-
views [1-5]. These reports suggested the following clinical
and pathological characteristics of PAL: a predominance
in elderly males, diffuse large B-cell lymphoma (DLBCL)
as the most common histology, frequent bilateral adrenal
involvement with insufficiency of adrenal function and a
tendency for patients to develop central nervous system
(CNS) infiltration. Some researchers have argued that
there may be a correlation between PAL and Epstein–Barr
virus infection [1,6], while others have reported that
tumor cells of primary adrenal DLBCL usually express
BCL-2 with a non-germinal center B-cell phenotype [7].
However, the accumulation of more information is needed
to further elucidate the clinicopathological features of
PAL. PAL has also been reported to generally have a poor
prognosis with conventional chemotherapy, such as the
CHOP regimen, and the optimal therapy for PAL remains
to be established. However, a substantial proportion of
cases reported in the literature were treated before the de-
velopment of rituximab, and it is possible that rituximab
would improve the prognosis of primary adrenal DLBCL,
as it does of typical DLBCL.
We herein analyzed the clinicopathological features and
clinical courses of seven cases of PAL encountered at our
institutions in recent years; all were pathologically diag-




From 2008 to 2011 in our institutions, seven cases were
newly diagnosed as primary adrenal DLBCL. We thor-
oughly reviewed their clinical and pathological findings
retrospetctively. The clinical features of the patients are
shown in Table 1. The patients ranged in age from 50 to
85 years, with a median of 71 years. The overall male:fe-
male ratio was 6:1. Only one patient (Case 5) presented
with symptoms of adrenal insufficiency and fever. The ad-
renal tumor of three cases (Cases 1, 2 and 3) was inciden-
tally found by a CT that was performed to evaluate other
underlying diseases, such as a renal tumor, chronic hepa-
titis and pulmonary fibrosis. The remaining three patients
had back pain. B-symptoms (fever, weight loss of more
than 10% within six months, or night sweating) were ob-
served in only one patient (Case 5).
The mean maximum diameter of the tumor at diagnosis
was 58 mm, with a range from 40 to 80 mm. Two patientswith unilateral adrenal involvement underwent surgical re-
section due to an initial suspicion of adrenal carcinoma. On
the other hand, the remaining five patients with bilateral
adrenal involvement were diagnosed by needle biopsy. Four
bilateral cases (Cases 3, 5, 6 and 7) had paraaortic lymph
node lesions; all of which were smaller than the adrenal le-
sions. These patients were stratified to be in a high-risk
group by the International Prognosis Index (IPI) [8]. No
additional lesions, including mediastinal and CNS lesions,
were detected in any cases on CT.
Positron emission tomography (PET) with 2-[18F] fluoro-
2-deoxy-D-glucose (FDG) was performed in all cases. The
uptake of FDG in the adrenal tumor was confirmed in all
cases, and in four cases, uptake was also detected in adja-
cent paraaortic lymph nodes. No other lesions with signifi-
cant FDG uptake were detected in any of the patients.
Uptake foci at the adrenal tumors were revealed in all cases,
and the maximum standardized uptake values (SUVmax)
in each case were generally high (8.0 – 26.0, median, 21.5).
The SUVmax seemed to be higher in the cases with bilateral
adrenal infiltration (n = 5; median, 22.4) than in the cases
with unilateral infiltration (n = 2; median, 15.5). In addition,
the values of the SUVmax in adjacent lymph nodes were all
lower than those in the adrenal tumors. Bone marrow infil-
tration was not detected in any of the patients.
Apparent CNS infiltration was not confirmed at the time
of diagnosis in any of the cases except in Case 4, in which
a brain tumor and bilateral adrenal tumors were detected
simultaneously. Both the cerebral and adrenal lesions were
biopsied and concluded to have the same histology as
DLBCL. In Case 5, multiple cerebral infarctions emerged a
month before the patient’s presentation to our institutions.
This may have been caused by the infiltration of lymphoma
cells toward cerebral vessels, although magnetic resonance
imaging of the brain and cytology of the cerebrospinal fluid
did not detect any infiltration of lymphoma cells.
The serum lactic dehydrogenase (LDH) level was above
the normal limits in all cases. The serum level of soluble
interleukin-2 receptor (sIL-2R) was also elevated in all six
cases in which it was measured. The rapid adrenocortico-
tropic hormone (ACTH) stimulation test, in which a
cortisol level less than 18 – 20 μg/dL at 60 minutes after
ACTH challenge is regarded to be a poor response [9],
revealed partial adrenal insufficiency in two cases with
bilateral adrenal involvement without clinically appar-
ent adrenal insufficiency.
Pathological analyses
The pathological and immunohistochemical findings of all
seven cases are shown in Table 2, and representative patho-
logical findings are shown in Figure 1. There were no
unique morphological characteristics of the PAL cases. All
cases were diagnosed as DLBCL. The tumor cells expressed
CD20 (7 of 7), CD79a (6 of 6), BCL2 (5 of 7), BCL6 (4 of 7)





















































IE-A 0 L-I Unilateral 80 [L] None 19.2 No lesions 376† 1374† 7.2 21.9
3/71/
M
Incidentaloma DLBCL CT-guided needle
biopsy
IIE-A 2 H-I Bilateral 52 [L] paraaortic
LNs [17]




Hemiparesis DLBCL CT-guided needle
biopsy








IIE-B 4 L-I Bilateral 57 [L] paraaortic
LNs [17]




Back pain DLBCL CT-guided needle
biopsy
IIE-A 3 H-I Bilateral 57 [L] paraaortic
LNs [39]




Back pain DLBCL CT-guided needle
biopsy
IIE-A 2 H-I Bilateral 67 [L] paraaortic
LNs [19]
21.5 8.6 529† 7777† 10.8 13.0‡
39 [R]
ACTH adrenocorticotropic hormone, CT computed tomography, DLBCL diffuse large B-cell lymphoma, F female, H high; H-I high-intermediate, IPI international prognosis index, L left, LDH serum lactate dehydrogenase,
L-I low-intermediate, LNs lymph nodes, M male, ND not done, PET positron emission tomography, PS performance status, R right, sIL-2R serum soluble interleukin-2 receptor, SUVmax maximum
standardized uptake value.
*Each serum cortisol level was measured at 60 min after ACTH challenge.




















Table 2 Summary of pathological and immunohistochemical findings
Case Pathological diagnosis CD5 CD10 CD20 CD79a BCL2 BCL6 EBER MUM1 Ki-67 index Phenotype
1 DLBCL, NOS − − + + + − + − 70-80% Non-GCB
2 DLBCL, NOS − − + + − + − − 90% GCB
3 DLBCL, NOS + − + + + − − + 80% Non-GCB
4 DLBCL, NOS − − + ND + + − + 75-90% Non-GCB
5 DLBCL, NOS + − + + + + − + 90-99% Non-GCB
6 DLBCL, NOS − − + + + + − + 75-90% Non-GCB
7 DLBCL, NOS − − + + − − − + 90-99% Non-GCB
DLBCL diffuse large B-cell lymphoma, GCB germinal center B-cell phenotype, ND not done, NOS not otherwise specified.
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was positive in two cases. The Ki-67 index was generally
high (> 70%). A flow cytometric analysis of the lymphoma
cells (data not shown) was available for Cases 6 and 7, and
did not conflict with the immunohistochemical data de-
scribed above. According to Hans’ criteria [10], most of the
cases (6 of 7) were classified as the non-germinal center B-
cell subtype.
Treatment and outcomes
All patients were treated with rituximab-containing chemo-
therapy, such as cyclophosphamide, doxorubicin, vincristine,Figure 1 Representative pathological findings of primary adrenal diff
right corner of each figure indicate 100 μm. (A, B) The results of hematoxy
was located in the zona reticularis (represented by r) of the adrenal cortex.
respectively. High-power magnification (B) showed medium- to large-sized
Immunohistochemical staining for CD20 showed that the large lymphoma
CD3 showed reactivity in small lymphocytes, but not in large lymphoma ceprednisolone and rituximab (R-CHOP), with a successful
clinical outcome (Table 3). The courses of chemotherapy
and the doses of agents were modified at the discretion of
the attending physicians according to the clinical condition
of the patients. In Case 4, because of the apparent coexist-
ence of CNS lymphoma, combined immunochemotherapy
plus whole-brain radiotherapy (WBRT), high-dose metho-
trexate (HD-MTX), high-dose cytarabine and rituximab,
was performed according to a previous report [11]. Case 5,
in which progression toward the CNS could not be ex-
cluded, received systemic intravenous administration of
high-dose methotrexate. Two additional cases (Cases 2use large B-cell lymphoma (Case 1). The black lines in the lower
lin and eosin staining. On low-power magnification (A), the lymphoma
f and g represent the zona fasiculata and zona glomerulosa,
atypical lymphoid cells with dispersed chromatin. (C)
cells were positive for CD20. (D) Immunohistochemical staining for
lls.
Table 3 Summary of clinical courses
Case Treatment Response to treatment Overall survival duration (months) Relapse Outcome Cause of death
1 R-CHOP ×5 PR 45.0 No Dead Cholangiocarcinoma
(75% dose)
2 R-CHOP ×6 PR 7.9 No Dead Pneumonia
IT*
3 R-CHOP ×2 NA 4.0 − Dead Exacerbation of pulmonary fibrosis
(70% dose)




5 R-CHOP ×6 CR 28.0 No Alive −
HD-MTX ×2
IT*
6 R-CHOP ×8 CR 24.8 No Alive −
IT*
7 R-COP ×1 NA 2.6 − Dead Pneumonia
(60% dose)
*IT represents prophylactic administration of methotrexate and/or cytarabine.
CR complete response, CRu unconfirmed complete response, HD-Ara-C high-dose cytarabine, HD-MTX high-dose methotrexate, IT intrathecal themotherapy, NA
not assessable, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, R-COP rituximab, cyclophosphamide, vincristine, and
prednisolone, R-MPV rituximab, high-dose methotrexate, procarbazine, and vincristine, WBRT Whole-brain radiotherapy.
Figure 2 The overall survival in all seven cases of PAL.
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methotrexate.
After the completion of chemotherapy, we assessed the
response in each case. CT scans were performed in all
cases, and FDG-PET was also performed in some cases
(Cases 4, 5 and 6). In the five patients who received a full
course of rituximab-containing chemotherapy and the
additional therapy mentioned above, a favorable clinical
outcome (complete response in Cases 4, 5 and 6, and par-
tial responses in Cases 1 and 2) was achieved, and there
have been no cases of relapse as of the writing of this
manuscript. The other two patients died of complications
during the course of chemotherapy (Case 3, exacerbation
of pulmonary fibrosis; Case 7, pneumonia). In both cases,
no signs of lymphoma progression, such as further eleva-
tion of the serum LDH level, were detected within their
clinical course after the initiation of chemotherapy.
The median survival time of all patients from diagno-
sis until death or the date of the last follow-up was 24.8
months (range, 2.6 – 45.0 months). No patients experi-
enced a relapse of lymphoma, and none died due to the
progression of lymphoma. Both the OS and FFS at two
years were 57.1% (95% CI 17.2 – 83.7, Figure 2).
Discussion
PAL is an extremely rare disease entity and only about 100
cases have been reported in the English literature to date.
The characteristics of our series of were largely consistentwith the previous reports; all were pathologically diag-
nosed as DLBCL, and the patients were predominantly
elderly males [1-4]. It might be unique that two cases were
positive for CD5 in our case series; for CD5-positive pri-
mary adrenal DLBCL cases have scarcely been reported
and only one case was reported recently [12]. However,
CD5 expression has not been evaluated even in some re-
cent studies which included a relatively large number of
primary adrenal DLBCL cases, and the significance of
CD5 expression in primary adrenal DLBCL remains to be
known. Three patients were asymptomatic at presentation,
and they were incidentally suspected to have adrenal
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another disease (i.e., incidentalomas). These observations
suggested that PAL might be more prevalent than has
been reported.
The definition of primary adrenal lymphoma has not been
made clear in the literature, unlike other rare extranodal
lymphomas, such as primary bone lymphoma [13] or pri-
mary breast lymphoma [14]. A common feature of the def-
inition of the two diseases mentioned above is that the
lymphoma arises in a specific extranodal organ, with or
without adjacent lymph node swelling. It is thought to be
reasonable that this definition is also applicable to primary
adrenal lymphoma (PAL). In our cases which had paraaortic
lymph node lesions (Cases 3, 5, 6 and 7), the size of the ad-
renal tumors was larger than that of the lymph node lesions
on CT (Table 1). Images of PET-CT scans showed that the
SUVmax of the adjacent lymph node lesions was also lower
than that of the adrenal lesions (Table 1). These findings
suggested that the adrenal lesion was the primary tumor in
each case. In Case 4, cerebral and adrenal lesions were
detected simultaneously. It is reported that DLBCL with ad-
renal involvement could have a tendency to develop CNS
infiltration [15], so we think that simultaneous involvement
of CNS and adrenal glands by lymphoma would be consid-
ered as PAL with secondary CNS involvement, as Rashidi A
et al. recently stated [16].
The most common symptoms of PAL at presentation
were reported to be abdominal or back pain, fever of un-
known origin and signs of adrenal insufficiency [1-4]. Bilat-
eral adrenal involvement of PAL is frequently accompanied
by clinical adrenal insufficiency [3,4,17-22]. In our series,
clinically definite adrenal insufficiency was seen in only
one of the five cases in whom the adrenal function was ex-
amined. The serum cortisol levels at baseline were not re-
duced in any of these cases. Partial adrenal insufficiency,
which was asymptomatic and detected by the rapid ACTH
test, was established in two cases of bilateral adrenal in-
volvement. Lymphoma cells show diffuse infiltration into
the adrenal parenchyma, and it is reasonable that bilateral
involvement of lymphoma would lead to a condition of ad-
renal insufficiency, even if it is not clinically obvious.
Gene expression studies of DLBCL have identified
two subtypes; the germinal-center B-cell-like (GCB)
subtype and the non-GCB subtype (combining the acti-
vated B-cell-like subtype and the type 3 subtype) [23];
the latter are associated with a significantly lower sur-
vival than the former. Moreover, Li et al. recently
showed that non-GCB DLBCL cases with high Ki-67 ex-
pression, which is an index of proliferation, received a
limited survival benefit from standard R-CHOP therapy
[24]. Following the Hans’ algorithm [10], we confirmed
that most of our cases were classified as the non-GCB
subtype, and all had high Ki-67 expression (over 70%).
In other previous reports [1,7], most PAL cases weresubclassified as the non-GCB type; these findings may
be associated with the poor prognosis of PAL.
In addition to the pathological factors mentioned above,
some clinical factors for predicting the prognosis of
DLBCL have recently been reported. For example, a high
sIL-2R level was reported to be associated with a poor
prognosis among patients with DLBCL who were treated
with R-CHOP [25]. It has also been reported that a high
SUVmax on PET scans is associated with a shorter sur-
vival in patients with DLBCL [26]. Moreover, Shou et al.
recently reported that lymphomas showing intense FDG
uptake have an increased capacity for proliferation and
rapid growth, which was confirmed by the Ki-67 expres-
sion [27]. In the present study, the bilateral cases had high
levels of sIL-2R and a high SUVmax on PET/CT com-
pared with unilateral cases. The Ki-67 index was also gen-
erally high in all cases. These points suggest that bilateral
adrenal DLBCL should be a clinically aggressive disease.
We successfully treated PAL patients in a tolerable gen-
eral condition with rituximab-containing systemic chemo-
therapy and CNS prophylaxis. PAL is frequently treated
with cyclophosphamide, doxorubicin hydrochloride, vin-
cristine and prednisolone (CHOP), or a CHOP-like regi-
men; however, the prognosis is generally poor [1,2]. In
recent years, rituximab has been added to the regimen,
and there have been a few reports about successful out-
comes with rituximab-containing regimens for PAL
[5,28,29]. However, CNS relapses of PAL occur frequently,
and most patients with CNS relapse are reported to have
died early [3,4,19,30,31]. We treated most of the patients in
the present study by R-CHOP, with modifications as neces-
sary, and added HD-MTX and/or intrathecal chemotherapy
for the patients who were considered to potentially have
CNS infiltration at presentation. It is noteworthy that all of
the patients who received a full course of rituximab-
containing chemotherapy and CNS-oriented treatment are
currently alive without disease progression or relapse. No
patients died of the progression of lymphoma, and there
were no cases of CNS relapse. This is despite the non-GCB
DLBCL subtype, elevated sIL-2R level and Ki-67 index
noted in these patients. Therefore, in younger PAL patients
in good general condition, an aggressive chemotherapeutic
strategy consisting of a rituximab-containing chemother-
apy regimen and CNS-oriented treatment is thought to be
promising, and could improve the prognosis of PAL.
Conclusions
PAL with DLBCL histology is a clinically aggressive dis-
ease. Rituximab-containing chemotherapy combined
with CNS prophylaxis could be a reasonable option for
the treatment of PAL; however, further accumulation of
clinical experiences, as well as additional research, is
necessary to establish the optimal therapeutic strategy
for PAL.
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Case selection and clinical data
From 2008 to 2011 in our institutions, a total of 563 pa-
tients were diagnosed with DLBCL. We reviewed the re-
cords of the patients with newly diagnosed primary adrenal
DLBCL. Cases with secondary adrenal involvement and
those with human immunodeficiency virus infection were
excluded. A total of seven cases were included in this study.
All had unilateral or bilateral adrenal tumors, which were
the predominant tumors considered to be primary lesions
(and were biopsied), while some other lesions, such as
paraaortic lymph node swelling or central nervous system
lesions, were also detected in several cases. The thera-
peutic strategy was chosen at the discretion of the attend-
ing physicians.
All available data, including the clinical presentations, la-
boratory findings, radiological findings, therapeutic regi-
mens and follow-up information, were evaluated. The
staging procedures included a complete physical examin-
ation, computed tomography (CT) scans of the neck, chest
and abdomen, positron emission tomography (PET) scans
and bone marrow biopsy and/or aspiration. This study was
approved by the Ethics Committee of each hospital. The
procedures performed for the present study were done in
accordance with the Declaration of Helsinki.
Pathological evaluation
Tissue specimens were fixed in 10% formalin solution,
routinely processed and embedded in paraffin. The sec-
tions were stained with hematoxylin-eosin for micro-
scopic examination. Immunohistochemical studies were
performed using antibodies against CD3, CD5, CD10,
CD20, CD45RA, CD79a, BCL2, BCL6, MUM1, Ki-67
and Epstein–Barr virus-encoded small RNA (EBER).
For two cases with sufficient materials available, flow
cytometry was performed using various monoclonal
antibodies against CD2, CD3, CD4, CD5, CD7, CD8,
CD10, CD13, CD19, CD20, CD22, CD30, CD45, CD56,
TCRαβ, TCRγδ, Igκ and Igλ. Markers that were
expressed on more than 20% of the cells were judged to
be positive.
Statistical analysis
All statistical analyses were performed using the GraphPad
Prism software program (version 5.04 for Windows;
GraphPad Software Inc., San Diego, CA). The treatment
outcomes were measured by the failure-free survival (FFS)
and overall survival (OS). The FFS was defined as the time
from initial diagnosis to the first occurrence of progression,
relapse after a response or death from any cause. The
follow-up of patients not experiencing one of these events
was censored at the date of last contact. The OS was mea-
sured from the time of the initial diagnosis until death
from any cause, with surviving patient follow-up censoredat the last contact date. Estimates of the FFS and OS were
determined using the Kaplan–Meier method.
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